Chemotherapy re-use versus anti-angiogenic monotherapy as the third-line treatment of patients with metastatic colorectal cancer: a real-world cohort study.

Authors:
Duan J; Zhu L; Shi Y; Wang W; Wang T and 13 more

Journal:
BMC Cancer

Publication Year: 2024

DOI:
10.1186/s12885-024-12072-5

PMCID:
PMC10916076

PMID:
38443891

Journal Information

Full Title: BMC Cancer

Abbreviation: BMC Cancer

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Neoplasms

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Declarations Ethics approval and consent to participateDue to the retrospective nature of this study, the ethical approval and informed consent requirements from each patient have been waived according to the regulations of the Tianjin Medical University Cancer Institute and Hospital Ethics Committee. Consent for publicationNot applicable. Competing interestsThe authors declare that they have no competing interests Competing interests The authors declare that they have no competing interests"

Evidence found in paper:

"Funding This work was supported by grants from the National Natural Science Foundation of China (Nos. 82103677) and Tianjin Key Medical Discipline (Specialty) Construction Project (TJYXZDXK-009 A)."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025